Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Jun 7;41(22):2058-2066.
doi: 10.1093/eurheartj/ehaa433.

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Chao Gao  1   2 , Yue Cai  1   3 , Kan Zhang  1   3 , Lei Zhou  3   4 , Yao Zhang  3   5 , Xijing Zhang  3   6 , Qi Li  3   7 , Weiqin Li  3   8 , Shiming Yang  3   9 , Xiaoyan Zhao  3   10 , Yuying Zhao  3   11 , Hui Wang  3   12 , Yi Liu  1 , Zhiyong Yin  1 , Ruining Zhang  1 , Rutao Wang  1   2 , Ming Yang  13 , Chen Hui  14 , William Wijns  2 , J William McEvoy  2 , Osama Soliman  2 , Yoshinobu Onuma  2 , Patrick W Serruys  2   15 , Ling Tao  1 , Fei Li  1   3
Affiliations
Observational Study

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Chao Gao et al. Eur Heart J. .

Abstract

Aims: It remains unknown whether the treatment of hypertension influences the mortality of patients diagnosed with coronavirus disease 2019 (COVID-19).

Methods and results: This is a retrospective observational study of all patients admitted with COVID-19 to Huo Shen Shan Hospital. The hospital was dedicated solely to the treatment of COVID-19 in Wuhan, China. Hypertension and the treatments were stratified according to the medical history or medications administrated prior to the infection. Among 2877 hospitalized patients, 29.5% (850/2877) had a history of hypertension. After adjustment for confounders, patients with hypertension had a two-fold increase in the relative risk of mortality as compared with patients without hypertension [4.0% vs. 1.1%, adjusted hazard ratio (HR) 2.12, 95% confidence interval (CI) 1.17-3.82, P = 0.013]. Patients with a history of hypertension but without antihypertensive treatment (n = 140) were associated with a significantly higher risk of mortality compared with those with antihypertensive treatments (n = 730) (7.9% vs. 3.2%, adjusted HR 2.17, 95% CI 1.03-4.57, P = 0.041). The mortality rates were similar between the renin-angiotensin-aldosterone system (RAAS) inhibitor (4/183) and non-RAAS inhibitor (19/527) cohorts (2.2% vs. 3.6%, adjusted HR 0.85, 95% CI 0.28-2.58, P = 0.774). However, in a study-level meta-analysis of four studies, the result showed that patients with RAAS inhibitor use tend to have a lower risk of mortality (relative risk 0.65, 95% CI 0.45-0.94, P = 0.20).

Conclusion: While hypertension and the discontinuation of antihypertensive treatment are suspected to be related to increased risk of mortality, in this retrospective observational analysis, we did not detect any harm of RAAS inhibitors in patients infected with COVID-19. However, the results should be considered as exploratory and interpreted cautiously.

Keywords: Angiotensin receptor blockers (ARBs); Angiotensin-converting enzyme inhibitors (ACEIs); Antihypertensive regimen; COVID-19.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Kaplan–Meier survival curves for mortality from the time of symptom onset. (A) Patients with or without hypertension, (B) patients with or without antihypertensive treatment, (C) patients with ACEI/ARBs (RAAS inhibitors), or beta-blocker, CCB, or diuretics (non-RAAS inhibitors),
Take home figure
Take home figure
Forest plot of the meta-analysis showing the mortality rates of those receiving RAAS inhibitors and non-RAAS inhibitors.
None
See this image and copyright information in PMC

Comment in

References

    1. Wu Z, McGoogan JM.. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–1242. - PubMed
    1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y.. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;doi: 10.1001/jamainternmed.2020.0994. - PMC - PubMed
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062. - PMC - PubMed
    1. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, Cowling BJ, Lipsitch M, Leung GM.. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 2020;26:506–510. - PMC - PubMed
    1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–280. - PMC - PubMed

Publication types

MeSH terms

Substances